• linkedin
  • Increase Font
  • Sharebar

    MET found safe, efficacious in pregnant stone patients

    Alpha-blocker should be included in treatment discussion, study author says


    Dr. Bailey observed that the pattern of symptomatic stone formation in pregnant women seen in the study was somewhat typical.

    ALSO SEE: Urologist self-referral increases likelihood of CT, ESWL

    "Pregnant women have the same risk of stone formation as their non-pregnant peers. Most pregnant women who present with symptomatic nephrolithiasis will do so in the second or third trimester. That trend was seen in our patient population," he said.

    He said that one of the challenges in treating stones in pregnant women is that the gold standard for imaging and localizing stones is computed tomography.

    "Obviously, radiation exposure is something we try to avoid in pregnant women. Often pregnant women with flank pain will undergo ultrasound imaging, which, unfortunately, has low sensitivity and specificity for stones. Women in our series were treated with tamsulosin, 0.4 mg/d, until the stone passed or their pain resolved," said Dr. Bailey. The study reported that the median duration of in-utero exposure to the agent was 3 days.

    ALSO SEE - Study: URS found superior to SWL in stones <1.5 cm

    Refractory renal colic requiring surgical intervention presented in eight patients (29%). This included one who required ureteral stent placement, one who required ureteroscopy without stent placement, five who required ureteroscopy with stent placement, and one who required a nephrostomy tube.

    NEXT: No significant differences seen compared to matched cohort without tamsulosin


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available